Jacinda C Abdul-Mutakabbir
Overview
Explore the profile of Jacinda C Abdul-Mutakabbir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Abdul-Mutakabbir J, Opoku N, Tan K, Jorth P, Nizet V, Fletcher H, et al.
Antibiotics (Basel)
. 2024 Jan;
13(1).
PMID: 38247606
With the increase in carbapenem-resistant (CRAB) infections, there has been a resurgence in the use of polymyxins, specifically colistin (COL). Since the reintroduction of COL-based regimens in treating CRAB infections,...
12.
McLeod C, Al-Fayiz H, Rodriguez S, Tan K, Abdul-Mutakabbir J
Antimicrob Steward Healthc Epidemiol
. 2023 Dec;
3(1):e214.
PMID: 38156210
Racially and ethnically minoritized (REM) patients are disproportionately impacted by infectious diseases. In our study, REM patients were more likely to receive care for urinary tract infections in the emergency...
13.
Morrison T, Wright W, Astle K, Abdul-Mutakabbir J
Am J Health Syst Pharm
. 2023 Dec;
81(8):326-333.
PMID: 38146922
No abstract available.
14.
Reveles K, Strey K, Abdul-Mutakabbir J, Mendoza V, Carreno J
Clin Infect Dis
. 2023 Dec;
77(Suppl 6):S455-S462.
PMID: 38051968
Infectious diseases are a leading contributor to death in the United States, and racial differences in clinical outcomes have been increasingly reported. Clostridioides difficile infection (CDI) is a growing public...
15.
Camara E, Safri A, Ko C, Abdul-Mutakabbir J, Bandali A, Brown B
J Am Pharm Assoc (2003)
. 2023 Oct;
64(1):34-38.e1.
PMID: 37865310
As the U.S. population becomes more racially and ethnically diverse, it is increasingly important to characterize health inequities for targeted intervention. As it stands, demographic data regarding race and ethnicity...
16.
Swartz T, Abdul-Mutakabbir J
FEMS Microbiol Lett
. 2023 Oct;
370.
PMID: 37863835
In academia, saying "yes" to opportunities and "no" to distractions is crucial for effective decision-making. Here, we emphasize the importance of carefully considering commitments and courageously declining those that may...
17.
Kebriaei R, Abdul-Mutakabbir J, Stamper K, Lev K, Rybak M
Infect Dis Ther
. 2023 Oct;
12(10):2485-2494.
PMID: 37798469
Introduction: Daptomycin (DAP) has proven to be a viable alternative amid vancomycin resistance; however, the use of DAP post vancomycin treatment has led to the development of DAP non-susceptible (DNS)...
18.
Wiley Z, Kalu I, Lyden E, Cichon C, Abdul-Mutakabbir J, Herskovitz J, et al.
Infect Control Hosp Epidemiol
. 2023 Oct;
45(4):422-428.
PMID: 37782036
Background: The Society for Healthcare Epidemiology of America (SHEA) is a leading medical society for infection prevention and antibiotic stewardship. This descriptive study evaluated speaker demographics at the annual SHEA...
19.
Tan K, Hino Jr G, Zhou A, Al-Fayiz H, Rodriguez S, Abdul-Mutakabbir J
Ther Adv Infect Dis
. 2023 Aug;
10:20499361231194257.
PMID: 37636217
Background: Outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (COpAT) are common practice in the management of infectious diseases (IDs). However, providing OPAT/COpAT can pose significant challenges pre-...
20.
Hong L, Downes K, FakhriRavari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S, et al.
Pharmacotherapy
. 2023 Aug;
43(8):740-777.
PMID: 37615245
Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are well established to display time-dependent bactericidal...